Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database.

ABSTRACT:

Background

Antifibrotics have been approved for use in many countries, including Japan, based on the results of several phase III clinical trials in patients with IPF, SSc-ILD, and PPF, which showed slower lung function decline with antifibrotic treatment. There is a paucity of information on the real-world use of antifibrotics in clinical practice.

Methods

Baseline characteristics, comorbidities, and drugs used prior to and concomitant with antifibrotics were collected for patients with IPF, SSc-ILD, and PPF using a health insurance claims database in Japan from 1 January 2013 to 30 June 2023. Descriptive statistics were generated for all study variables.

Results

This study included 657 nintedanib users with IPF; 418 pirfenidone users with IPF; 4160 nintedanib users

SUBMITTER: Kondoh Y 

PROVIDER: S-EPMC12096679 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature